Phase I evaluation of vascular disrupting agent OXi4503

被引：0
|
作者：
Patterson, D. M.
Charnley, N.
Saleem, A.
Stratford, M.
Dickinson, C.
Asselin, M.
Ross, P.
Walicke, P.
Price, P.
Rustin, G. J.
机构：
[1] Mt Vernon Hosp, Northwood HA6 2RN, Middx, England
[2] Christie Hopsital, Manchester, Lancs, England
[3] Gray Canc Inst, Northwood, Middx, England
[4] Canc Res UK, London, England
[5] Oxigene, Waltham, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3551
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I evaluation of OXi4503, a vascular disrupting agent, in patients with advanced solid tumours
    Patterson, D. M.
    Ross, P.
    Koetz, B.
    Saleem, A.
    Stratford, M.
    Stirling, J.
    Padhani, A.
    Asselin, M.
    Price, P.
    Rustin, G. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Interim results from a phase I trial of the vascular disrupting agent OXi4503
    Patterson, Daniel M.
    Ross, Phillip
    Koetz, Barbara
    Saleem, Azeem
    Stratford, Mike
    Stirling, James
    Padhani, Anwar
    Asselin, Marie-Claude
    Price, Pat
    Rustin, Gordon J.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3436S - 3436S
  • [3] The Vascular Disrupting Agent OXi4503 in Relapsed and Refractory AML and MDS
    Stockton, Shannon Somer
    Pettiford, Leslie
    Cline, Christina
    Chaplin, David
    Hsu, Jack W.
    Wingard, John R.
    Cogle, Christopher R.
    [J]. BLOOD, 2015, 126 (23)
  • [4] Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors
    Patterson, Dan M.
    Zweifel, Martin
    Middleton, Mark R.
    Price, Patricia M.
    Folkes, Lisa K.
    Stratford, Michael R. L.
    Ross, Phil
    Halford, Sarah
    Peters, Jane
    Balkissoon, Jai
    Chaplin, Dai J.
    Padhani, Anwar R.
    Rustin, Gordon J. S.
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (05) : 1415 - 1425
  • [5] Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial
    J Cummings
    M Zweifel
    N Smith
    P Ross
    J Peters
    G Rustin
    P Price
    M R Middleton
    T Ward
    C Dive
    [J]. British Journal of Cancer, 2012, 106 : 1766 - 1771
  • [6] Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial
    Cummings, J.
    Zweifel, M.
    Smith, N.
    Ross, P.
    Peters, J.
    Rustin, G.
    Price, P.
    Middleton, M. R.
    Ward, T.
    Dive, C.
    [J]. BRITISH JOURNAL OF CANCER, 2012, 106 (11) : 1766 - 1771
  • [7] Enhancing stereotactic radiation schedules using the vascular disrupting agent OXi4503
    Horsman, M. R.
    Wittenborn, T. R.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S107 - S107
  • [8] Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity
    Salmon, Howard W.
    Siemann, Dietmar W.
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (13) : 4090 - 4094
  • [9] Preclinical Activity of the Vascular Disrupting Agent OXi4503 against Head and Neck Cancer
    Bothwell, Katelyn D.
    Folaron, Margaret
    Seshadri, Mukund
    [J]. CANCERS, 2016, 8 (01)
  • [10] Therapeutic potential of using the vascular disrupting agent OXi4503 to enhance mild temperature thermoradiation
    Horsman, Michael R.
    [J]. INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2015, 31 (05) : 453 - 459
12345